Table 4. Univariate and multivariate analysis of prognostic factor for OS.
| Factors | No. of patients | Median OS (mo.) | P | Hazard ratio (95%CI) | P |
|---|---|---|---|---|---|
| Treatment method | 0.177 | ||||
| Raltitrexed group | 40 | 7.4 | |||
| Control group | 46 | 5.8 | |||
| Sex | 0.666 | ||||
| Male | 79 | 6.3 | |||
| Female | 7 | 8.2 | |||
| Age (years) | 0.960 | ||||
| ≤ 60 | 61 | 6.3 | |||
| > 60 | 25 | 7.4 | |||
| ECOG Performance status |
0.567 | ||||
| 0 | 8 | 9.8 | |||
| 1-2 | 78 | 6.3 | |||
| HBsAg | 0.635 | ||||
| Negative | 20 | 6.2 | |||
| Positive | 66 | 6.8 | |||
| BCLC stage | ﹤0.001 | 0.140 (0.069, 0.285) | ﹤0.001 | ||
| Stage B (intermediate) | 28 | 12.5 | |||
| Stage C (advanced) | 58 | 5.7 | |||
| Tumor number | 0.195 | ||||
| Single | 9 | 12.7 | |||
| Multiple | 77 | 6.6 | |||
| Child-pugh class | 0.216 | ||||
| A | 71 | 6.8 | |||
| B | 15 | 5.6 | |||
| AFP, ng/mL | 0.019 | 0.110 | |||
| ≤ 400 | 36 | 8.6 | |||
| > 400 | 50 | 5.8 | |||
| Tumor size, cm | 0.023 | 0.360 | |||
| ≤ 10 | 63 | 7.4 | |||
| > 10 | 23 | 5.7 | |||
| Extrahepatic metastases | 0.002 | 0.648 | |||
| Absence | 60 | 7.4 | |||
| Presence | 26 | 5.8 | |||
| Portal vein tumor thrombus | ﹤0.001 | 0.380 | |||
| Absence | 32 | 10.9 | |||
| Presence | 54 | 5.7 | |||
| Ascites | 0.682 | ||||
| Absence | 75 | 6.8 | |||
| Presence | 11 | 6.3 |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; HbsAg, Hepatitis B surface antigen; BCLC, Barcelona Clinic Liver Cancer; AFP, Alpha-fetoprotein.